



## STUDY OF CORRELATION OF HUMAN PAPILLOMA VIRUS WITH ORAL CAVITY & OROPHARYNGEAL SQUAMOUS CELL CARCINOMA.

**Satpinder kaur\***

Resident, Department Of Otorhinolaryngology, Dr. D. Y. Patil Medical College, Kolhapur, Maharashtra, India. \*Corresponding Author

**Rajashri Mane**

Professor and HOD, Department Of Otorhinolaryngology, Dr. D. Y. Patil Medical College, Kolhapur, Maharashtra, India.

**Vishal Salhotra**

Resident, Department Of Pathology, Indira Gandhi medical college, Shimla, Himachal Pradesh, 171001

**Anjana Mohite**

Associate Professor, Department Of Otorhinolaryngology, Dr. D. Y. Patil Medical College, Kolhapur, Maharashtra, India.

### ABSTRACT

A prospective cohort clinical study was carried out at Dr.D.Y.Patil Hospital & Research Institute, Kolhapur from May 2014-May 2016. An attempt was made to correlate the Human Papilloma Virus in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. Real time Polymerase Chain Reaction technique using consensus HPV primers was used to detect HPV type 16 & HPV type 18 in punch biopsy specimens from 70 patients of oral cavity & oropharyngeal squamous cell carcinoma. Data was collected from all patients by giving questionnaire and statistically analysed by applying chi-square test. 83.33% of HPV were detected in Oral cavity Squamous cell carcinoma & 16.66% of HPV were detected in Oropharyngeal Squamous cell carcinoma. Among HPV positive, majority 66.66% were HPV type 16, 33.33% were HPV type 16 & HPV type 18 combined. HPV positive cases showed better prognosis & overall survival as compared to HPV negative cases. Thus we conclude that HPV positive cancers differ significantly from HPV negative cancers with regards to patient's age, gender, addiction, site of tumour and stage.

**KEYWORDS :** Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Human Papilloma Virus .

### INTRODUCTION

Head and neck cancer encompasses epithelial malignancies that arise in the paranasal sinuses, nasal cavity, oral cavity (including the buccal mucosa, upper and lower alveolar ridges, retromolar trigone, floor of the mouth, hard and soft palate and anterior two thirds of the tongue), oropharynx, nasopharynx, hypopharynx, pharynx, and larynx[1]. The incidence and mortality of head and neck cancer varies throughout the world. Globally, it is the sixth most common cancer type, accounting for 6 % of all cases, and responsible for 650 000 new cancer cases annually with a mortality of 350 000 cases annually worldwide[2]. The Indian sub-continent accounts for one-third of the world burden. The incidence and mortality from oral cancer is rising in several regions of Europe, Taiwan, Japan and Australia. About 90 percent of head and neck cancers are of the squamous cell variety. Oral cancer is the most common cancer in India; as 4 in 10 of all cancers are oral cancers. Annually 130,000 people succumb to oral cancer in India which translates into approximately 14 deaths per hour. The reason for high prevalence of oral cancer in India is primarily because tobacco is consumed in the form of gutka, quid, snuff or misri. Rising tobacco use in India, where 40 per cent of the world's smokers live has contributed to this trend. . In India, 20 per 100000 population are affected by oral cancer which accounts for about 30% of all types of cancer[3]. Over 5 people in India die every hour everyday because of oral cancer[4]. In India, cancer of the oral cavity and oropharynx is the commonest cancer in men and third commonest cancer in women [5]. Oral cancers are more common in males than females. However, there is a rise in the incidence of these malignancies in females. Oral cavity cancer incidence in males is 50,174 (10.9%) and in female is 28,245(0.53%) whereas oropharyngeal cancer incidence in males is 39,098(0.5%) and in females 13,132 (0.16%) [6]. Incidence of oral cancers in patients with risk factors is 8.4 times higher than that of patients who do not have any risk factors and male to female ratio is 3:1. This ratio is seen in most of the published studies in India. Oral cancers implies quite significant mortality and

morbidity rates and in spite of the vast amount of research and the advances accomplished in the field of oncology and surgery, the mortality rates remain unchanged. This motivates the search of factors with prognostic relevance in order to better tailor the individual management of OSCC patients. The purpose of this article is to list and discuss various factors, mainly focusing on HPV correlation with Oral & Oropharyngeal cancers.

**Epidemiology :** Despite increased understanding of oral cancer carcinogenesis, fully supported by the most recent technology including combined treatment modalities of oral cancer management, diagnosis has not improved significantly with regard to the 5 year overall survival rates for the disease over the past three decades especially in the United Kingdom (UK)[7][8]. Based on global incidence, the group of oral and oropharyngeal cancers rank sixth among human cancers[8]. Geographic variations in oral cancer incidence are greatly influenced by factors such as genetic, habits and lifestyle[9]. High-risk countries for oral cancer are India, Pakistan, Sri Lanka and Bangladesh. About 95% of all oral cancer cases occur in people over the age of 50 and twice as frequently in men as in women. Nowadays, a new trend of oral cancer in young people before the age of 40 is emerging and the male:female ratio has been changing significantly, from 5:1 to 2:1, over the last five decades. In Asian populations, the buccal mucosa is the most common intraoral site for mouth cancer, whereas tongue is the commonest among European and US cases[8].

#### Risk factors for oral cancer:

It is widely considered that the major risk factors for oral cancer are tobacco smoke [10] [11], alcoholic beverage drinking [10] or synergy between the former and later factors [12].

**Tobacco smoking:** More than 300 carcinogens are present in either tobacco smoke or its water-soluble components in heavy smokers' saliva [11]. The first 69 carcinogens were previously reported and categorised into eleven groups. It was

observed that dose-related tobacco smoking practice (i.e. the frequency of cigarettes smoking and duration of smoking) is strongly associated with oral cancer[13][14][15].

**Smokeless tobacco:** Smokeless tobacco is an alternative way of consuming tobacco, whereby combustion is not required. Nevertheless, nasal snuff in various forms (loose or small packet), and chewing tobacco (in block or flakes) still keeps mucous membranes in contact with the carcinogenic agents[16].

Among the other factors, Betel quid or arecanut chewing, alcohol & dietary factors have been associated as a major risk factors for Head & Neck squamous cell carcinoma [17][18][19][20].

#### HPV as risk factor

Over the last 10-15 years HPV infection has been increasingly recognized as a major aetiological factor for HNSCCs[21][22][23][24], mostly OPSCC. HPV infection in the aetiology of OPSCC was first shown by Gillison et al.[25], numerous case series and studies conducted in the late 1990s and early 2000s evaluated the prevalence HPV infection in oropharyngeal cancer using molecular techniques such as PCR and in situ hybridization[22][26][27]. Over the last five years it has become increasingly clear that HPV plays a pathogenic role in this subset of head and neck cancers, with distinct epidemiologic, clinical and molecular characteristics. These findings have created new opportunities for improved therapy and primary prevention for these HNSCCs[28].

HPV is a DNA oncovirus and is epitheliotropic. Approximately 200 HPV genotypes belonging to 49 species have been recognized by the International HPV Reference Centre. These genotypes have been sequenced and classified according to their phylogenetic position, biological niche and oncogenic potential with new types discovered regularly. The genera alpha, beta, gamma, mu and nu types infect the humans. Novel -HPV types are believed to be present in oral cavity of healthy individuals also. Most recently, a novel HPV type 199 (HPV199) was identified in a nasopharyngeal swab sample[29]. There are 30–40 genotypes from the -genus of HPVs that infect the human genital tract. Based on their oncogenic potential, they can be subdivided into low- and high-risk types. Low-risk HPV types include HPV6 and 11 which have been associated with benign warts or condylomata. By contrast, there is at least 12 high risk HPV types, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59. They have been associated with at least six different cancers as well as precursor neoplastic lesions. HPV 16 and 18 are well-established initiators of 90% of cervical cancers, 70% of anogenital cancers, 5% of non-oropharyngeal SCC[30] and 20-72% of OPSCC [30][31][32].

#### MATERIALS & METHODS:

A Prospective cohort clinical study was carried out at Dr.D.Y.Patil Hospital & Research institute, Kolhapur(MAHARASHTRA), from May 2014 to May 2017, after obtaining approval from the ethical committee of the institute. All patients attending the E.N.T., outpatient department, with oral lesions, were screened & examined. Punch Biopsy was taken & sent for the histopathological report. The patients with positive for Squamous Cell Carcinoma were included in the study. The paraffin embedded blocks were prepared & sent for HPV DNA detection. HPV DNA detection & genotyping of these blocks was performed by pathologist. The WHO grading system was used for the histopathological grading of oral cavity and oropharyngeal squamous cell carcinomas. This system is largely based on the Broders classification and uses three grades Grade I (Well differentiated), Grade II (Moderately differentiated) and Grade III (Poorly differentiated)[33]. The

staging of oral cavity and oropharyngeal cancers was based on the TNM system of the American Joint Committee on Cancer (AJCC)[34]. On the basis of stage at presentation the patients were divided into two groups: those with early stage disease (Stage I/II) and those with late stage disease (Stage III/IV).

Prevalence of HPV infection in oral and oropharyngeal malignancies was evaluated by Human Papilloma Viruse types 16 & 18 Fluorescent Real Time Polymerase Chain Reaction Diagnostic test. Chi-square test was employed to test the association of different variables with HPV status and a p value of more than 0.05 was taken as insignificant.

- **PCR TECHNIQUE:** Genomic DNA was isolated from the biopsy tissue by phenol–chloroform extraction method[35]. PCR was carried out with the HPV consensus primers MY09/11. The details of primers are as follows:
- MY 09 5' —CGT CCAAAA GGAAAC TGA Tc—3' .
- MY 11 5' —GCA CAG GGACAT AAC AAT Gg—3' .
- GP5+ 5' —TTT GTT ACT GTG GTA GAT ACT Ac—3' .
- GP6+ 5' —GAA AAA TAA ACT GTA AAT CAT ATT C—3' .

MY(consensus primer), GP(general primer) and TS (type-specific primer). Initial denaturation step at 95°C for 5 minutes, followed by 40 cycles of denaturation at 55°C for 1 minute, annealing at 55°C for 1 minute and extension at 72°C for 10 minutes.

Sample positive for general primer, were further evaluated for HPV genotype 16 & 18 using type specific primer (TS 16 & Ts18). PCR was performed using 300ng DNA as template. Results were analysed on 1.5% agarose gel containing 0.5µg/ml ethidium. The products were electrophoresed on 1.5% agarose gel and stained with ethidium bromide. A band at 450 base pair specific for HPV was seen. Lane N: negative control, Lane P: positive control, Lanes 1-4 HPV (general primer) positive tumour samples, Lanes 5-6 HPV 16 positive tumour samples, Lanes 7-8 HPV 18 positive tumour samples, Lane L: molecular size marker (450bp ladder marker) Figure 1.

#### RESULTS:

Of the 70 cases of oral cavity and oropharyngeal malignancies, 61(87.14%) were males and 9(12.87%) were females (Figure 2). Mean age at diagnosis was 53.28 ± 11.21 year, where majority 52.85% patients were in age group of 41 to 60 years, followed by 28.57% in more than 60 years and only 18.57% were in 21 to 40 years of age group (Figure 3).

It was found that 64(91.42%) patients were having addiction in different forms and 6(8.57%) were not (Figure 4). Among Non addiction group, all were positive for HPV whereas in addiction group, all were negative for HPV.

It was observed that 57(81.42%) patients had malignancy of oral cavity and 13(18.57%) had malignancy of oropharynx. In the HPV positive group, 5(83.33%) patients had malignancy of oral cavity and 1(16.66%) had malignancy of oropharynx. Whereas among HPV negative patients 52(81.25%) had malignancy of oral cavity and 12(18.75%) had malignancy of oropharynx (Figure 5, 7).

Among the 70 patients, 2(2.85%) patients had stage I malignancy, 30(42.85%) had stage II, 10(14.28%) had stage III and 28(40%) had stage IV malignancy. 1(1.42%) of our patient in stage I underwent surgery with neck dissection, 1(1.42%) patient underwent surgery without neck dissection, all were subjected to post-operative radiotherapy. 18(25.71%) of our patients in stage II underwent surgery with neck dissection,

12(17.14%) patients underwent surgery without neck dissection, 29(41.42%) were subjected to postoperative radiotherapy and only one(1.42%) underwent postoperative chemotherapy. All of our patients In stage III underwent surgery with neck dissection & were subjected to postoperative chemotherapy. 4(20%) of our patients in stage IV underwent surgery with neck dissection, 14(20%) underwent surgery without neck dissection & majority were subjected to postoperative chemotherapy and only one was subjected to postoperative radiotherapy(Table 1).

It was observed that in a total 70 patients of oral cavity and oropharyngeal carcinomas 6 (8.57%) were found to be HPV positive and 64(91.42%) were found to be HPV negative by PCR technique(Figure 6). Among HPV positive, majority 4 (66.66%) were HPV type 16, 2(33.33%) were HPV type16 & HPV type18 combined.

Among the 70 patients it was observed that 39 (55.71%) patients had well differentiated malignancy, 25 (35.71%) had moderately differentiated malignancy and 6 had poorly differentiated malignancy. In HPV positive cases, 6(8.57%) all were poorly differentiated. However in HPV negative cases, 39(55.71%) were well differentiated, 25(35.71%) were moderately differentiated and no one was poorly differentiated(Figure8).

In present study, 6 (8.57%) were detected as HPV positive, out of which 83.33% were disease free, 16.67% were lost to follow up, whereas 64 (91.42%) were HPV negative, out of which 82.81% were disease free, 6.25% were lost to follow up & 7.83% were expired (Table 2). HPV positive cases showed better prognosis and overall survival rate as compared to HPV negative cases. As p value <0.001 i.e. p value <0.05 which shows significance (Figure 9).

## DISCUSSION:

India is a high-risk region for oral and oropharyngeal cancers due to a high prevalence of tobacco use, particularly chewing (in both sexes), bidi smoking and alcohol drinking in male population. Tobacco and alcohol are the two most important known risk factors for the development of oral cancer. Cofactors in oral squamous cell carcinoma include dietary factors, immunodeficiency and viral infections like HPV 16/18. PCR study for HPV was done in 70 patients out of which 8.57% were positive & rest were negative. The same was true in other studies (Prashad et al<sup>[36]</sup>, M.L Gilision et al<sup>[37]</sup>, Tanu Agrawal et al<sup>[38]</sup>, Akhter M et al<sup>[39]</sup>, Ashutosh et al<sup>[40]</sup>).

The reported rates of detection of HPV DNA in oral cavity & oropharyngeal squamous cell carcinoma in various studies range from 0% to 100%. The extreme variation in reported prevalence may be owing to lumping together of essentially different lesions, to different sample numbers ranging from 2 to 100 samples and to difference in sampling techniques (use of frozen or paraffin embedded tissue sample). In the ethnographic origins of the subjects examined and in the HPV detection methods applied. Considering the participants understanding of the definition of oral sex, one should be cautious in interpreting these figures.

The range of age group in our study was 18 years & above. Mean age was 53.28 ± 11.21 years. The minimum age of the patients in our study was 28 and maximum was 75 years. Maximum numbers of patients were in the age group between 41 to 60 years. The same was noted in other studies (Saghravanian N et al<sup>[41]</sup>, Saklain MA et al<sup>[42]</sup>, JS Polling et al<sup>[43]</sup>). Oral HPV infection is considered to be bimodal in age distribution, with a high prevalence in younger (30-50 years of age) & in later years (60-64 years). The patients who were HPV +ve in our study were between 46 and 70 years of age. It has been speculated that the higher HPV prevalence at

younger age could be due to different sexual behavior, whereas at older ages could be due to increased duration of infections at older age, rather than increased acquisition of new HPV infections.

In present study it was seen that males comprised 87.14% and females comprised 12.87% showing male preponderance. This finding was similar to the study by Saghravanian N et al<sup>[41]</sup>, M.L Gilision et al<sup>[37]</sup>.

The history of tobacco and alcohol use was found to be less common in HPV positive patients than HPV negative patients. Study by CL Davidson et al<sup>[44]</sup>, showed that 80% were drinkers, 46.4% were smokers, 40.8% were practiced oral sex. Study by Ashutosh et al<sup>[102]</sup>, showed that 37% were habituated to combined addiction, 27.5% were drinkers, & 0.3% were practiced oral sex. In western studies oral sex was common risk factor, but in our study none of the patient gave history of oral sex. The reason for this may be social enigma. In western countries, oral sex is practiced commonly but in India this is not. In our study there were some patients who didn't have any addiction, but were positive for HPV. Probably reason for this may be that they were practicing oral sex but did not commit. In the present study, the most frequent subsites of involvement in carcinoma of oral cavity were buccal mucosa (60%) & in carcinoma of oropharynx were base of tongue (17.14%). The same was true in other studies. (Smith et al<sup>[45]</sup>, Sanjeev Parshad et al<sup>[36]</sup>, Ashutosh et al<sup>[40]</sup>, Kristina R. Dahlstrom et al<sup>[46]</sup>, Daniel Brandizzi et al<sup>[47]</sup>) Buccal mucosa is most common site for oral cavity malignancy in India. This is chiefly attributable to the common habit of placing tobacco & betel quid in gingival sulcus. In oropharynx, base of tongue is most common site in our study & same was reported in western countries because of smoking.

In our study, majority (42.85%) had stage II lesions, whereas in other studies (Sannigrahi et al<sup>[48]</sup>, Smith et al<sup>[45]</sup>) more number of cases were found to be in stage III & stage IV. When diagnosed at early stage, prognosis & overall survival rate were better.

The histopathological grading of oral & oropharyngeal malignancy cases in the present study showed that among HPV positive patients all were poorly differentiated SCC 6(100%), whereas among HPV negative patients, 39(60%) were WDSCC followed by 25(39.06%) were MDSCC and none were PDSCC. According to review of literature in published studies, HPV positive cancers have been recognized as a separate entity. They have different histologic features, do not undergo significant keratinization & are usually poorly differentiated. The same was true in our study.

In our study, among HPV positive, majority 66.66% were HPV type 16, 33.33% were HPV type16 & HPV type18 combined. Studies by Herrero RC et al<sup>[49]</sup>, Balaram et al<sup>[50]</sup>, Nagpal JK et al<sup>[51]</sup>, Dcosta J et al<sup>[52]</sup>, they had detected other HPV genotypes along with HPV type16 & HPV type18. In our study we had detected HPV only for High risk types (HPV type16 & HPV type 18) which are most commonly associated with oral cancers. We studied only two genotypes HPV type16 & HPV type18 to keep the study cost effective.

In present study, most of the patients were subjected to postoperative chemotherapy in stage IV 27(38.57%), postoperative radiotherapy in stage II 29(41%) & some to chemotherapy. Whereas in a study by Klaus DW et al<sup>[53]</sup> postoperative radiotherapy or radiochemotherapy were given in advanced stage. According to literature, HPV positive cancers give better response to radiotherapy.

In our study follow up period ranged from 3 months to 1 year. Among the 70 patients 15(27.27%) had mucositis, 13(23.63%)

had flap necrosis, 10(18.18%) showed pigmentation, 3(5.45%) had recurrence of disease, 1(1.81%) had xerostomia, 1(1.81%) had swelling, 1(1.81%) had trismus and 1(1.81%) had dysphagia. Study by Astrid L Kruse et al<sup>[54]</sup>, during his follow up period of 1 year, among the 67 patients 22.38% had recurrence of disease, 14.92% had distant metastasis and 4.47% had distant metastasis & recurrence of disease combined. In a study by Saghravanian N et al<sup>[41]</sup>, 30.30% had recurrence of disease, 2% had distant metastasis & 1% had second primary cancer. In present study, most of the patients had radiation mucositis & only 5.45% had recurrence of disease who took inadequate postoperative radiotherapy. None of the patients showed distant metastasis.

In our study, HPV positive cases showed better prognosis & overall survival rate. As p value <0.001 i.e. p value <0.05 which shows significance. It is well established that HPV positive cases have better prognosis as compared to HPV negative cases.

In our study, 83.33% of HPV were detected in oral cavity Squamous cell carcinoma and only 16.66% of HPV were detected in Oropharyngeal Squamous cell carcinoma, whereas in other studies (M.L Gilision et al<sup>[37]</sup>, Tanu Agrawal et al<sup>[38]</sup>) most of HPV cases were detected in oropharyngeal malignancy, but in our study only 16.66% of HPV were detected in oropharyngeal malignancy in whom who had no addiction.


In our study, association of HPV in oral cavity & oropharyngeal malignancy was insignificant (p value >0.05) by chi-square test (Figure 10).

In conclusion, HPV positive cancers differ significantly from HPV negative cancers with regards to patient's age, gender, addiction, site of tumor & stage. However, more Indian studies are required before HPV may be recognized as tumorigenic factor in Oral cancers.


**DECLARATIONS**

Funding: None  
 Conflict of Interest: None  
 Ethical Approval: Not Required


**Figure 1. PCR amplification of HPV general, HPV type 16 and HPV type 18**




**Figure 2. Gender wise Distribution**




**Figure 3. Age wise distribution**



**Figure 4. Distribution of Addiction type**



**Figure 5. Distribution of sites among oral cavity and oropharynx**



**Figure 6: HPV detection by Polymerase Chain Reaction**






Figure 7: Presence Of HPV in Oral Cavity & Oropharynx




Figure 8: Histological Grading & its association with HPV presence




Table 1. TNM staging & treatment given in different stages

TNM staging	No. of patients	Percentage
Stage I	2	2.85%
Stage II	30	42.85%
Stage III	10	14.28%
Stage IV α	28	40%

Stages	Oral cavity/Oropharynx (%)	Surgery (%)	With neck dissection (%)	Without neck dissection (%)	Chemotherapy (%)	Radiotherapy (%)
Stage I	2(2.84)	2(2.84)	1(1.42)	1(1.42)	0(0)	2(2.85)
Stage II	30(42.85)	30(42.85)	18(25.71)	12(17.14)	1(1.42)	29(41.42)
Stage III	10(14.28)	10(14.28)	10(14.28)	0(0)	10(14.28)	0(0)
Stage IV	28(40)	28(40)	14(20)	14(20)	27(38.57)	1(1.42)

Table 2: Follow up done to the patients

Parameter	No of patients	Percentage
Recurrence	3	5.45%
Flap necrosis	13	23.63%
Pigmentation	10	18.18%
Mucositis	15	27.27%
Xerostomia	1	1.81%
Swelling	1	1.81%
Trismus	1	1.81%
Dysphagia	1	1.81%

Figure 9: Prognosis





Figure 10: Association of HPV in Oral cavity & Oropharynx



REFERENCES:

- Marur S, and Forastiere AA. Head and neck cancer: Changing epidemiology, diagnosis and treatment. *Mayo Clin Proc* 2008; 83(4): 489-501
- Argiris A, Karamouzis M, Raben D, Ferris RL. Head and neck cancer-Seminar

- Lancet 2008; 371(9625) : 1695-1709
- R Sankaranarayanan, K Ramadas, G Thomas et al., "Effect of screening on oral cancer mortality in Kerala, India: a cluster randomised controlled trial," *The Lancet* 2005, 365(9475):1927-1933. Varshitha, A/J. *Pharm. Sci. & Res.* 2015;7(10), 845-848.
- Bhawna Gupta, Anura Ariyawardana, Newell W, Johnson. "Oral cancer in India continues in epidemic proportions: evidence base and policy initiatives" *International Dental Journal* 2013; 63:12-25
- J. K. Elango, P. Gangadharan, S. Sumithra, and M. A. Kuriakose. "Trends of head and neck cancers in urban and rural India," *Asian Pacific Journal of Cancer Prevention*, 2006 Vol. 7. no. 1, pp. 108-112.
- Shalini Gupta, Rajender Singh, O. P. Gupta, Anurag Tripathi. "Prevalence of oral cancer and precancerous lesions and the association with numerous risk factors in North India: A hospital based study". *Natl J Maxillofac Surg.* 2014 Jul-Dec; 5(2): 142-148.
- Rapidis A.D, Gullane P, Langdon J.D, Lefebvre J.L, Scully C. and Shah J.P. Major advances in the knowledge and understanding of the epidemiology, aetiopathogenesis, diagnosis, management and prognosis of oral cancer. *Oral Oncol* 2009; 45(4-5): 299-300
- Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. *Oral Oncol* 2009; 45(4-5): 309-316
- Moore S.R, Johnson N.W, Pierce A.M. and Wilson D.F. The epidemiology of mouth cancer: a review of global incidence. *Oral Dis* 2000; 6(2): 65-74
- International Agency for Research against Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans. Alcohol Drinking. IARC Lyon France, 1988; 44
- International Agency for Research against Cancer. Tobacco smoke and Involuntary Smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Lyon France, 2004; 83
- International Agency for Research against Cancer. Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Lyon France, 2007; 89
- Rodu B. and Jansson C. Smokeless tobacco and oral cancer: a review of the risks and determinants. *Crit Rev Oral Biol Med* 2004; 15(5): 252-263
- International Agency for Research against Cancer. Smokeless Tobacco. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Lyon France, 2006; 89
- Weitkunat R, Sanders E, and Lee PN. Meta-analysis of the relation between European and American smokeless tobacco and oral cancer. *BMC Public Health* 2007; 7: 334
- Rodu B and Godshall W.T. Tobacco harm reduction: an alternative cessation strategy for inveterate smokers. *Harm Red J* 2006; 3(37): 1-23
- Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado M.P et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *J Natl Cancer I* 2007; 99(10): 777-789
- Ho T, Wei Q and Sturgis E.M. Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. *Head Neck* 2007; 29(7): 682-99
- Thomas S.J, Bain C.J, Battistutta D, Ness A.R, Paissat D and MacLennan R. Betel quid not containing tobacco and oral cancer: A report on a case-control study in Papua New Guinea and a meta-analysis of current evidence. *Int J Cancer* 2007; 120(6): 1318-1323
- Lucenteforte E, Garavello W, Bossetti C. and La Vecchia C. Dietary factors and oral and pharyngeal cancer risk. *Oral Oncol* 2009; 45(6): 461-467
- Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the US population ages 20- 44 years. *Cancer.* 2005;103:1843-1849.

22. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papilloma virus and rising oropharyngeal cancer in the United States. *J Clin Oncol.* 2011;29:4294-4294.
23. Sedrak M, Rizzolo D. Understanding the link between hpv and oropharyngeal cancer. *JAAPA.*2009;22:42-46.
24. McKeon-Cowdin R, Feigelson HS, Ross RK, et al. Declining cancer rates in the 1990s. *J Clin Oncol.*2000;18:2258-2268.
25. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papilloma virus and a subset of head and neck cancers. *Natl Cancer Inst.* 2000;92:709-720.
26. Gillison ML. Human papilloma virus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. *Semin Oncol.* 2004;31:744-754.
27. Singhi AD, Westra WH. Comparison of human papilloma virus in situ hybridization and p16 immunohistochemistry in the detection of human papilloma virus-associated head and neck cancer based on a prospective clinical experience. *Cancer.* 2010;116:2166-2173.
28. Adelstein DJ, Rodriguez CP Human papilloma virus: changing paradigm in oropharyngeal cancer. *Curr Oncol Rep.* 2010;12:115-120.
29. Oštrbenk A, Kocjan BJ, Hošnjak L, Li J, Deng Q, et al. Identification of a Novel Human Papilloma virus, Type HPV199, Isolated from a Nasopharynx and Anal Canal, and Complete Genomic Characterization of Papilloma virus Species Gamma-12. *PLoS ONE.* 2015; 10: e0138628.
30. Sturgis EM, Ang KK. The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms? *J Natl Compr CancNetw.* 2011;9:665-673.
31. Monsjou HS, Balm AJ, Brekel MM, et al. Oropharyngeal squamous cell carcinoma: a unique disease on the rise? *Oral Oncol.* 2010;46:780-785.
32. Robinson KL, Macfarlane GJ. Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing? *Oral Oncol.* 2003;39:31-36.
33. Doshi NP, Shah SA, Patel KB, Jhabuawala M. Histological grading of oral cancer: A comparison of different systems and their relation to lymph node metastasis. *National Journal of Community Medicine.* 2011; 2: 136 - 142.
34. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. (Eds.) *The AJCC Cancer Staging Manual*, ed. 7. New York, 2010, Springer.
35. Sambrook J, Fritsch EF, and Maniatis T. *Molecular Cloning: A Laboratory Manual*. 2nd edition. New York: Cold Spring Harbor Laboratory Press; 1989.
36. Sanjeev Parshad, Sourabh Nandi, Nisha Marwah, Promod Mehta, Mayank Tripathi, Netrapal, Shekhar Gogna, RK Karwasra. Human papillomavirus 16 and 18 in squamous cell carcinoma of oral cavity and sexual practices: A pilot study at a Tertiary Care Hospital of North India. *National Journal of Maxillofacial Surgery.*2015;Vol6, Issue 2: 185-189.
37. Maura L, Gillison, Wayne M, Koch, Randolph B, Capone, Michael Spafford, William H. Westra, Li Wu, Marianna L. Zahurak, Richard W. Daniel, Michael Viglione, David E. Symer, Keerti V. Shah, David Sidransky. *J Natl Cancer Inst* 2000;92: 709-20
38. Tanu Agrawal, Tripti Garg, Jaspreet Kaur, Rohit Sharma, Ratna Saxena. "Prevalence of Human Papilloma Virus in Oral and Oropharyngeal Squamous Cell Carcinomas". *Journal of Evolution of Medical and Dental Sciences* 2015; Vol. 4, Issue 50, June 22; Page: 8623-8631, DOI: 10.14260/jemds/2015/1249.
39. Mahmuda Akhter, Liaquat Ali, Zahid Hassan, Imran Khan. Association of Human Papilloma Virus Infection and Oral Squamous Cell Carcinoma in Bangladesh. *J HEALTH POPUL NUTR* 2013 Mar;31(1):65-69 ISSN 1606-0997.
40. Ashutosh Tondare, Aditya Adhav, Incidence of head & neck cancers in cancer centres in Maharashtra, *Arch of Head & Neck Surg.* 2016; voll issue 1, 5-12.
41. Nasrollah Saghravanian,1 Maryam Zamanzadeh,2 Zahra Meshkat,3 Monavar Afzal Aghae,4 and Roham Salek5. Evaluation of the Prevalence Rate and the Prognostic Effect of Human Papilloma Virus Infection in a Group of Patients With Oral Cavity Squamous Cell Carcinoma. *Iran J Cancer Prev.* 2016 June; 9(3):e3998.
42. Saklain MA,1 Rahman MZ,2 Nasreen M,3 Haque AE,4 Sarker JN5. Association of Human Papilloma Virus Type 16 and 18 with Squamous Cell Carcinoma in Oral Cavity and Oropharynx. *Dinajpur Med Col J* 2015 Jul; 8 (2):137-143.
43. JS Poling, X-J Ma, S Bui, Y Luo, R Li, WM Koch, and WH Westra . Human papillomavirus (HPV) status of non-tobacco related squamous cell carcinomas of the lateral tongue. *Oral Oncology* April 2014 Volume 50, Issue 4, Pages 306-310.
44. Davidson CL, Richter KL, Van der Linde M, Coetsee J, Boy SC. Prevalence of oral and oropharyngeal human papillomavirus in a sample of South African men: a pilot study. *S Afr Med J.* 2014 Mar 26; 104(5):358-61.
45. Smith, E.M., et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. *Int J Cancer.* 2004. 108(5): p. 766-72.
46. Kristina R. Dahlstrom, Karen Adler-Storthz, Carol J. Etzel, Zhensheng Liu, Laura Dillon, Adel K. El-Naggar, Margaret R. Spitz, John T. Schiller, Qingyi Wei, and Erich M. Sturgis. Human Papillomavirus Type 16 Infection and Squamous Cell Carcinoma of the Head and Neck in Never- Smokers: A Matched Pair Analysis. *Clin Cancer Res* July 2003; 9: 2620-2626.
47. Daniel Brandizzi, Mariana Gandolfo, María Lucia Velazco, Rómulo Luis Cabrini, Hector Eduardo Lanfranchi . Clinical features and evolution of oral cancer: A study of 274 cases in Buenos Aires, Argentina. *Med Oral Patol Cir Bucal.* 2008 Sep 1;13(9):E544-8.
48. Sannigrahi MK, Singh V, Sharma R, Panda NK, Radotra BD, Khullar M. Detection of active human papilloma virus-16 in head and neck cancers of Asian North Indian patients. *Oral Dis.* 2016 Jan;22(1):62-8.
49. Herrero R, Castellsagu X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. *J Natl Cancer Inst* 2003;95:1772-83.
50. P Balaram , K R Nalinakumari , E Abraham , A Balan , N K Hareendran , H U Bernard , S Y Chan. Human Papilloma Viruse in 91 Oral Cancers from Indian betel quid chewers , high prevalence and multiplicity of infections. *Int J Cancer* 1995 May16;61(4):450-454.
51. Nagpal JK, Patnaik S, Das BR .Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. . *Int J Cancer.* 2002 Feb 10;97(5):649-53.
52. D'Costa J, Saranath D, Dedhia P, Sanghvi V, Mehta AR. Detection of HPV-16 genome in human oral cancers and potentially malignant lesions from India. *Oral Oncol* 1998;34:413-20.
53. Klaus-Dietrich Wolff, Markus Follmann, Alexander Nast. The Diagnosis and Treatment of Oral Cavity Cancer. *Deutsches Ärzteblatt International | Dtsch Arztebl Int* 2012; 109(48): 829 - 35.
54. Astrid L Kruse , Marius Bredell , Klaus W Gratz . Oral squamous cell carcinoma in non- smoking and non- drinking patients. *Head & Neck Oncology* 2010,2:24.